BioSpace News Archive

Howland will manage the North Carolina office and will be instrumental in serving the firm’s existing and new clients in the state.

Fresh campaign breaks traditional medical aesthetics marketing approach to stomp out the stigma and tap into a new segment of women, The Reclaimers

The global machine vision camera market research report by Technavio predicts the market to post a CAGR of close to 9% during the period 2018-2022.

Move positions company to bring a new standard of care to U.S. hospitals in effort to improve cardiac arrest outcomes

Eighty-six percent of senior business leaders from companies with annual revenues greater than $1 billion forecast organizational growth for 2019, yet less than 30 percent feel prepared to address their top priorities, according to the annual North Highland Beacon, released today by global management consulting firm North Highland.

Shelley Amster has worked in the life science and health industries for more than 30 years, beginning with her research on infertility.

BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after receiving up to one additional line of therapy1

At today’s meeting, the Supervisory Board of Sartorius AG resolved to make changes in the Executive Board. Effective January 1, 2019, Dr. René Fáber as Head of the Bioprocess Solutions Division and Gerry Mackay as Head of the Lab Products & Services Division will be appointed new members of the company’s Executive Board.

For the second year in a row, cereal growers can enter for a chance to win a $5,000 donation from Bayer to a charity of their choice through the Grain for Good™ Sweepstakes presented by the Bayer Cereal Experts.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that a clinical development program is underway with Novartis to bring to market a molecular test as a companion diagnostic to guide the use of the investigational compound BYL719 (alpelisib) in combination with fulvestrant for men and postmenopausal women living with PIK3CA mutated hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.